PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 12685300

[Second generation antipsychotics: similarities and differences].

Marek Jarema·Janusz Rybakowski·Jerzy Landowski
View original source ↗Export metadata ↓

Abstract

Second generation antipsychotics share some similarities but display also differences in their action. The pharmacological profile as well as the clinical efficacy and tolerability of these drugs currently on the market in Poland have been described. The analysis of their properties reveals distinct differences between the drugs. Those differences underline the value of the medications in the treatment of psychotic disorders. The differences allow tailoring the antipsychotic therapy to the individual needs of each single patient. Such a possibility to use the pharmacological agents according to the needs of the patient makes an important feature of the second generation drugs. At the same time it indicates that obvious differences in action exist inside the group.

Explore related subjects

Antipsychotic AgentsDose-Response Relationship, DrugHumansPsychotic DisordersSchizophreniaEnglish AbstractJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Marek Jarema, Janusz Rybakowski, Jerzy Landowski. [Second generation antipsychotics: similarities and differences].. https://pubmed.ncbi.nlm.nih.gov/12685300/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Estimating transitions between symptom severity states over time in schizophrenia: a Bayesian meta-analytic approach.

We obtain the posterior predictive distribution of transition probabilities between symptom severity states over time for patients with schizophrenia by (i) employing a Bayesian meta-analysis of published clinical trials and observational studies to estimate the posterior distribution of parameters that guide changes in Positive and Negative Syndrome Scale (PANSS) scores over time and under the influence of various drugs and (ii) by propagating the variability from the posterior distributions of the parameters through a micro-simulation model that is formulated based on schizophrenia progression. Results show detailed differences among haloperidol, risperidone and olanzapine in controlling various levels of severities of positive, negative and joint symptoms over time. For example, risperidone seems best in controlling severe positive symptoms while olanzapine is the worst in that during the first quarter of drug treatment; however, olanzapine seems to be best in controlling severe negative symptoms across all four quarters of treatment while haloperidol is the worst in this regard. These details may further serve to better estimate quality of life of patients and aid in resource utilization decisions in treating schizophrenic patients. In addition, consistent estimation of uncertainty in the time-profile parameters also has important implications for the practice of cost-effectiveness analysis and for future resource allocation policies in schizophrenia treatment.

Antipsychotic Agents↗
PubMed2006

Investigation of the phenylalanine hydroxylase gene and tardive dyskinesia.

Phenylketonuria (PKU), an inborn error of phenylalanine metabolism, has been shown to be a risk factor for tardive dyskinesia (TD). In male psychiatric patients there was a significant relationship between TD and measures of plasma phenylalanine following ingestion of a standardized phenylalanine dose that was indicative of higher brain availability of phenylalanine in patients with TD. In addition, a medical food formulation consisting of branched chain amino acids, which compete with phenylalanine for transport across the blood-brain barrier, has been demonstrated to be an efficacious treatment for TD. Cumulatively these findings suggested that TD was related to phenylalanine metabolism and thus that sequence variants in the gene for phenylalanine hydroxylase (PAH), the rate-limiting enzyme in the catabolism of phenylalanine, could be associated with TD susceptibility. Genetic screening of PAH in a group of 123 psychiatric patients revealed ten sequence polymorphisms and two mutations, but none appeared to be a significant risk factor for TD.

Antipsychotic Agents↗